Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;21(5):330-335.
doi: 10.1038/s41577-021-00544-9. Epub 2021 Apr 1.

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination

Affiliations
Review

Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination

Sarah Cobey et al. Nat Rev Immunol. 2021 May.

Abstract

When vaccines are in limited supply, expanding the number of people who receive some vaccine, such as by halving doses or increasing the interval between doses, can reduce disease and mortality compared with concentrating available vaccine doses in a subset of the population. A corollary of such dose-sparing strategies is that the vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine-escape variants, ultimately undermining vaccine effectiveness. We argue that, although this is possible, preliminary evidence instead suggests such strategies should slow the rate of viral escape from vaccine or naturally induced immunity. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence of efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution.

PubMed Disclaimer

Conflict of interest statement

M.L. has received honoraria/consulting from Sanofi–Pasteur, Bristol Myers Squibb and Merck; receives research funding (institutional) from Pfizer; and has provided unpaid scientific advice to Pfizer, Janssen, AstraZeneca, One Day Sooner and Covaxx (United Biomedical). Y.H.G. has received consulting fees from GSK and Merck not related to the subject of this manuscript, and research funding (institutional) from Pfizer and Merck also unrelated to this work. D.B.L. and S.C. declare no competing interests.

Figures

Fig. 1
Fig. 1. Potential vaccine-induced evolution.
a | Vaccination increases the transmission advantage of an escape variant compared with wild type (WT). Here, vaccine escape is complete, allowing the variant to replace the wild type in vaccinated hosts. b | If residual immune protection from vaccination slows the transmission of the variant, the variant cannot spread as readily in the vaccinated population, reducing prevalence and incidence. c | Within hosts, ‘intermediate’ immune pressure could in theory maximize the rate of adaptation. After two doses of vaccine, strong immune responses will likely inhibit viral replication and the emergence of escape mutations. Some have proposed that with just one dose, the rate of within-host adaptation could be high (triangle at top of the curve). We suggest that selection during COVID-19 infections is inefficient (triangle to lower right of curve). Adapted with permission from refs,, AAAS.

References

    1. World Health Organization. COVAX Global Supply Forecast (WHO, 2021).
    1. Tuite AR, Zhu L, Fisman DN, Salomon JA. Alternative dose allocation strategies to increase benefits from constrained COVID-19 vaccine supply. Ann. Intern. Med. 2021 doi: 10.7326/M20-8137. - DOI - PMC - PubMed
    1. Barnabas RV, Wald A. A public health COVID-19 vaccination strategy to maximize the health gains for every single vaccine dose. Ann. Intern. Med. 2021 doi: 10.7326/M20-8060. - DOI - PMC - PubMed
    1. Paltiel AD, Zheng A, Schwartz JL. Speed versus efficacy: quantifying potential tradeoffs in COVID-19 vaccine deployment. Ann. Intern. Med. 2021 doi: 10.7326/M20-7866. - DOI - PMC - PubMed
    1. Riley S, Wu JT, Leung GM. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med. 2007;4:e218. doi: 10.1371/journal.pmed.0040218. - DOI - PMC - PubMed

Publication types